Back to Agenda
PDUFA at 25: A Historical View of the Prescription Drug User Fee Agreement and a Look to the Future - PDUFA VI
Session Chair(s)
Kim Quaintance-Lunn
Vice President, Head of Regulatory Science and Execution, Alexion Pharmaceuticals, United States
Development and approval timelines for drugs and therapeutic biologic products affect us all. This will be the first reauthorization occurring in parallel with a new Congress and a new administration. This session will focus on how PDUFA has affected both the regulator and regulated industry and what we can expect in the sixth iteration of the agreement.
Learning Objective : Discuss a historical review of PDUFA from expediting approvals to expediting development; Identify what's new in PDUFA VI and the impact on sponsor and regulator.
Speaker(s)
Theresa Mullin, PHD
Associate Center Director - CDER, FDA, United States
Panelist
Patrick Frey
Senior Director, Regulatory Policy, Neurocrine Biosciences, United States
FDA Perspective
Sandy Milligan, JD, MD
Board of Director Member, Gossamer Bio; Principal, Innovex Strategies, United States
Industry Perspective
Lucy Vereshchagina, PHD
Vice President, Science and Regulatory Advocacy, PhRMA, United States
Panelist
Have an account?